First human trial begins for new schizophrenia pill
NCT ID NCT07344948
Summary
This is the first study in humans to test the safety and how the body processes an experimental oral medication called NTX-253, being developed for schizophrenia. It will involve healthy adults and adults with stable schizophrenia who temporarily stop their regular antipsychotic medication. Researchers will give single and multiple doses to check for side effects and measure drug levels in blood and spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Collaborative Neuroscience Research, LLC - CenExel
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.